Business
InflaRx Announces Participation in February Investor Conferences
JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in several investor conferences in February 2026. Details are as follows: Guggenheim Securities Emerging Outlook: Biotech Summit 2026February 11 - 12, 2026 in New York, NYFireside chat on Wednesday, February 11 at 11:30 AM ET InflaRx will also conduct one-on-one investor meetings
About this update from Inflarx N.v.
[{"type":"image","alt":"InflaRx N.V.","displaySize":"","headline":null,"caption":"InflaRx N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lqiU0gFIS0tiIdhYPTjZSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a","width":300,"height":157}},"lazy":false},{"type":"text","content":"JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in several investor conferences in February 2026. Details are as follows:","length":293,"tagName":"p"},{"type":"text","content":"Guggenheim Securities Emerging Outlook: Biotech Summit 2026February 11 - 12, 2026 in New York, NYFireside chat on Wednesday, February 11 at 11:30 AM ET","length":153,"tagName":"p"},{"type":"text","content":"InflaRx will also conduct one-on-one investor meetings on February 11th. A link to view the fireside chat live stream and its replay is available here.","length":151,"tagName":"p"},{"type":"text","content":"Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 25 - 26, 2026 in a virtual formatVirtual presentation on February 25 at 8:40 AM ET","length":152,"tagName":"p"},{"type":"text","content":"InflaRx will also conduct one-on-one investor meetings on February 25th. A link to view the virtual presentation and its replay is available here.","length":146,"tagName":"p"},{"type":"text","content":"About InflaRxInflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical stu...